Phase III
AM-111 failed to meet its primary endpoint, although the company is putting a positive spin on it by noting it was effective in a subpopulation.
The drug developed by Alkermes took a lot of flack but proved effective in a recent study.
Cytokinetics has suspended development of tirasemtiv after it failed to differentiate itself from placebo in a statistically significant manner.
Ardelyx updated two of its programs today.
Researchers are making great headway against cancer, even though it’s currently still the second-leading cause of death in the U.S.
There were five fatalities out of seven patients with sepsis, all in the tozadenant group.
The company is weeks away from completing its rolling NDA for Patisiran.
Genentech announced that its Phase III HAVEN 3 study of Hemlibra in adults and adolescents with hemophilia A without inhibitors to factor VIII had positive results.
Acorda Therapeutics updated its Phase III clinical trial of tozadenant for Parkinson’s disease.
New data shows Repatha hit its primary endpoint and significantly reduced first-time cardiovascular events by 27 percent in PAD patients.
PRESS RELEASES